Dr. Bradley A McGregor, MD
Claim this profileDana Farber Cancer Institute
Affiliated Hospitals
Dana Farber Cancer Institute
Brigham & Womans Hospital
Clinical Trials Bradley A McGregor, MD is currently running
Sacituzumab Govitecan + Enfortumab Vedotin
for Bladder Cancer
Phase I of this research study will assess what doses of Sacituzumab Govitecan and Enfortumab Vedotin can be safely combined in the treatment of metastatic urothelial carcinoma (mUC). In Phase II of the study, patients in one of the two cohorts will receive Sacituzumab Govitecan, Enfortumab Vedotin, and Pembrolizumab to assess the efficacy of this drug combination. The names of the study drugs in these investigational combinations are: * Enfortumab Vedotin * Sacituzumab Govitecan * Pembrolizumab
Recruiting
1 award
Phase 1 & 2
16 criteria
Stereotactic Radiation + Immunotherapy
for Kidney Cancer
This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with renal cell cancer that is not recommended for surgery and has spread from where it first started (primary site) to other places in the body (metastatic). Radiation therapy uses high energy photons to kill tumor cells and shrink tumors. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses of radiation over a shorter period and cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, avelumab, and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib, cabozantinib, and lenvatinib are in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving SABR in combination with standard of care immunotherapy may help shrink or stabilize the cancer in patients with renal cell cancer.
Recruiting
1 award
Phase 2
21 criteria
More about Bradley A McGregor, MD
Clinical Trial Related
5 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Bradley A McGregor, MD has experience with
- Ipilimumab
- Nivolumab
- Cabozantinib
- Enfortumab Vedotin
- Sacituzumab Govitecan
- TAK-228
Breakdown of trials Bradley A McGregor, MD has run
Kidney Cancer
Renal Cell Carcinoma
Bladder Cancer
Kidney Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Bradley A McGregor, MD specialize in?
Bradley A McGregor, MD focuses on Kidney Cancer and Renal Cell Carcinoma. In particular, much of their work with Kidney Cancer has involved Stage IV patients, or patients who are undergoing treatment.
Is Bradley A McGregor, MD currently recruiting for clinical trials?
Yes, Bradley A McGregor, MD is currently recruiting for 2 clinical trials in Boston Massachusetts. If you're interested in participating, you should apply.
Are there any treatments that Bradley A McGregor, MD has studied deeply?
Yes, Bradley A McGregor, MD has studied treatments such as Ipilimumab, Nivolumab, Cabozantinib.
What is the best way to schedule an appointment with Bradley A McGregor, MD?
Apply for one of the trials that Bradley A McGregor, MD is conducting.
What is the office address of Bradley A McGregor, MD?
The office of Bradley A McGregor, MD is located at: Dana Farber Cancer Institute, Boston, Massachusetts 02215 United States. This is the address for their practice at the Dana Farber Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.